Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma

DuVall, Adam S.; Wesevich, Austin; Larson, Richard A.

doi:10.1007/s11899-023-00706-7

Cited by 1 publication

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 However, despite promising results using targeted therapies in early-phase clinical trials, 2 nelarabine is currently the only FDAapproved drug for the management of R/R T-ALL. 3,4 With salvage chemotherapy response rates ranging from 15% to 25% and a 5-year survival <30%, R/R T-ALL represents a major unmet need for drug development. 5 Agents approved for R/R ALL are now being incorporated into front-line therapy, [6][7][8] which highlights the need for new treatment options if these patients subsequently relapse or prove refractory.…”

Section: Introductionmentioning

confidence: 99%

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors

Madero‐Marroquin,

DuVall,

Saygin

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryData regarding the use of FMS‐like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3‐ or IDH1/2‐mutated ALL. Three early T‐cell precursor‐ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations.

show abstract